Skip to content

The EveryLife Foundation Launches National Burden of Rare Disease Survey

Share this page

With an estimated 30 million Americans living with a rare disease, it is understood that the cost of rare disease – both economically and socially – is immense. Yet, no one has previously examined the true cost on a large scale in the United States. Today, the EveryLife Foundation for Rare Diseases, a public policy nonprofit organization, launched the National Burden of Rare Disease Survey to capture the financial and social cost of rare diseases.

“It is essential for every rare disease patient in America to take this survey,” said Annie Kennedy, EveryLife Foundation for Rare Diseases Chief of Policy and Advocacy. “Every day, millions of Americans carry the heavy financial burden of rare disease – losing time from work, paying for treatments and medical equipment not covered by insurance, financing home and vehicle modifications to accommodate their disease progression, and paying for personal caregivers. These costs must be taken into consideration by decision makers when forming healthcare policy. The patient community’s participation in this survey will provide the much-needed data to advance policies that will improve the lives of rare disease patients and families for decades to come.”

A disease is defined as rare when it affects fewer than 200,000 people in the United States. On average, rare disease patients must wait an average of six years after symptoms first present before receiving a proper diagnosis. Ninety-three percent of the 7,000 known rare diseases have no U.S. Food and Drug Administration-approved therapies. Fifty percent of rare disease patients are children, thirty percent of whom will not live to see their fifth birthdays.

The EveryLife Foundation for Rare Diseases developed this survey in collaboration with the rare disease community and health economists.

All survey respondent data is anonymous. The aggregated results (weighted to reflect the larger underlying population) will be released in a journal manuscript later this year.

The deadline to take the survey is Monday, August 3rd. Rare Disease patients should visit BurdenStudy.org to learn more and to take the survey.

###

About the EveryLife Foundation for Rare Diseases
The EveryLife Foundation for Rare Diseases is a 501(c)(3) nonprofit, nonpartisan organization dedicated to advancing the development of treatment and diagnostic opportunities for rare disease patients through science-driven public policy. The Foundation does not speak for patients, but instead provides the training, education, resources, and opportunities to make patient voices heard. By activating the patient advocate, the Foundation believes it can change public policy and save lives.

This groundbreaking study was made possible with support from the following partners: Mallinckrodt Pharmaceuticals, Sanofi Genzyme, Retrophin, Sarepta Therapeutics, Alexion Pharmaceuticals, Genentech, PhRMA, REGENXBIO and Spark Therapeutics.

The Foundation receives funding from philanthropic organizations, government, individual donors, and corporations to support its activities. Sponsors are offered recognition for their support, but do not influence Foundation policy priorities or event program content. View our complete funding policy.

Related Articles